The Use of an Automated, Portable, Glucose Control System for Overnight Glucose Control in Adolescents and Young Adults With Type 1 Diabetes
Diabetes Care, 08/10/2012
O'Grady MJ et al. – The results suggest that the Portable Glucose Control System (PGCS), an automated closed–loop device, is safe and effective in achieving overnight glucose control in patients with type 1 diabetes.Methods
- This study was designed to investigate the efficacy and safety of a fully automated, portable, closed–loop system.
- The Medtronic Portable Glucose Control System (PGCS) consists of two subcutaneous glucose sensors, a control algorithm based on proportional–integral–derivative with insulin feedback operating from a BlackBerry Storm smartphone platform, Bluetooth radiofrequency translator, and an off–the–shelf Medtronic Paradigm Veo insulin pump.
- Participants with type 1 diabetes using insulin pump therapy underwent two consecutive nights of in–clinic, overnight, closed–loop control after a baseline open–loop assessment.
- Eight participants attended for 16 overnight studies.
- The PGCS maintained mean overnight plasma glucose levels of 6.4 ± 1.7 mmol/L (115 ± 31 mg/dL).
- The proportion of time with venous plasma glucose <3.9, between 3.9 and 8 (70 and 144 mg/dL), and >8 mmol/L was 7, 78, and 15%, respectively.
- The proportion of time the sensor glucose values were maintained between 3.9 and 8 mmol/L was greater for closed–loop than open–loop (84.5 vs. 46.7%; P < 0.0001), and time spent <3.3 mmol/L was also reduced (0.9 vs. 3%; P < 0.0001).